Markets:

Overview

News

Currencies

International

Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

65.48 -5.33 (-7.53%)

Streaming Delayed Price Updated: 10:55 AM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout ↗

November 23, 2021

The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.

Via The Motley Fool

Arrowhead Pharmaceuticals, inc (ARWR) Q4 2021 Earnings Call Transcript ↗

November 22, 2021

ARWR earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results

November 22, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD

November 22, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022 ↗

November 22, 2021

Alnylam is working on a drug that could tackle transthyretin cardiomyopathy.

Via Investor's Business Daily

Earnings Scheduled For November 22, 2021 ↗

November 22, 2021

Companies Reporting Before The Bell • Cerence (NASDAQ:CRNC) is estimated to report quarterly earnings at $0.56 per share on revenue of $97.92 million. • Avaya...

Via Benzinga

The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗

November 21, 2021

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting...

Via Talk Markets

The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗

November 21, 2021

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the...

Via Benzinga

Earnings Outlook For Arrowhead Pharmaceuticals ↗

November 19, 2021

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is set to give its latest quarterly earnings report on Monday, 2021-11-22. Here's what investors need to know before the announcement....

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 18, 2021

Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA) shares moved upwards by 78.87% to $38.06 during Thursday's regular session. As of 12:30 EST, this security is trading at...

Via Benzinga

Arrowhead Announces JNJ-75220795 in Development for NASH

November 17, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection

November 15, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021

November 15, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting

November 12, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting

November 12, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results

November 01, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences

November 01, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases

October 25, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases

October 12, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia

September 30, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences

September 29, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Earns $10 Million Phase 1 Milestone Payment

September 28, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences

September 01, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals, inc (ARWR) Q3 2021 Earnings Call Transcript ↗

August 06, 2021

ARWR earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Recap: Arrowhead Pharmaceuticals Q3 Earnings ↗

August 05, 2021

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 123.08%...

Via Benzinga

Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results

August 05, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease

July 29, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals: Buy the Dip? ↗

July 19, 2021

This biotech underdog offers more than meets the eye.

Via The Motley Fool

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results

July 14, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

July 14, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.